Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 19, 2021 - Issue 1
Submit an article Journal homepage
73
Views
0
CrossRef citations to date
0
Altmetric
Letter to the editor

Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention

Alvaro Garcia-Roperoa Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UKCorrespondence[email protected]
,
Carlos G. Santos-Gallegob Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, USA
&
Juan J. Badimonb Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, USA
Pages 101-102 | Received 17 Aug 2020, Accepted 30 Sep 2020, Published online: 27 Oct 2020

References

  • Katsiki N, Kotsa K, Kotsis V. Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention [published online ahead of print, 2020 Sep 16]. Expert Rev Cardiovasc Ther. 2020 Sep 16:1–2.
  • Garcia-Ropero A, Santos-Gallego CG, Vargas-Delgado AP, et al. Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. [published online ahead of print, 2020 Aug 9]. Expert Rev Cardiovasc Ther. 2020 Sep;18(9):635–642.
  • Asensio-Lopez M, Lax A, Hernandez-Vicente A, et al. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Sci Rep. 2020;10:13553.
  • Byrne N, Parajuli N, Levasseur J, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci. 2017;2:347–354.
  • Garcia-Ropero A, Santos-Gallego CG, Zafar MU, et al. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;1–11. Available from. [Internet].
  • Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
  • Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931–1944.
  • SantosGallego C, Requena-Ibanez J, Antonio RS, et al. Infusion of the ketone body β-hydroxybutyrate improves left ventricular systolic function in an animal model of heart failure with reduced ejection fraction. AHA Abstract. 2018;138.
  • Kang S, Verma S, Teng G, et al. Direct effect of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG OUTCOME. Abstr Can J Cardiol. 2017;33:S169.
  • García-Ropero A, Santos-Gallego C, Badimon J. The anti-inflammatory effects of SGLT inhibitors. Aging (Albany NY). 2019;11:5866–5867.
  • Santos-Gallego C, Badimón J. High-density lipoprotein and cardiovascular risk reduction: promises and realities. Rev Esp Cardiol. 2012;65:305–308.
  • Verma S, Mazer C, Yan A, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140:1693–1702.
  • Packer M, Anker S, Butler J, et al., EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. Advance online publication.
  • Di Franco A, Cantini G, Tani A, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol. 2017;243:86–90. Available from. [Internet].
  • Li Z, Agrawal V, Ramratnam M, et al. Cardiac Sodium-Glucose Co-Transporter 1 (SGLT1) is a novel mediator of ischemia/reperfusion injury. Cardiovasc Res. 2019;115:1646–1658.
  • Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. [Internet]. 2018;1–16. Available from https://www.tandfonline.com/doi/full/10.1080/17425255.2018.1551877

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.